HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...
Hosted on MSN1mon
Merck posts mixed late-stage trial results for HIV treatmentThe open-label MK-8591A-051 trial was designed to evaluate doravirine/islatravir against baseline antiretroviral therapy, and the double-blind MK-8591A-052 trial evaluated the combo against FDA ...
UNAIDS is calling on the U.S. and global leaders to prevent a public health crisis. Aid cuts could lead to millions of new ...
Hosted on MSN1mon
MSD’s DOR/ISL regimen meets primary efficacy hypotheses in HIV-1 treatment trialsUS-based pharmaceutical company MSD has reported positive results from two Phase III trials of doravirine/islatravir (DOR/ISL), an oral treatment regimen being assessed in adults with ...
The landscape of HIV prevention has undergone a profound transformation with significant advancements in medical interventions and a deeper understanding of how the virus spreads. These ...
London: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as ...
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria plus Rekambys for HIV treatment in adolescents: London, UK Saturday, February 1, 2025, 11:00 Hrs ...
GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback